This content is from: Premium
Where EcoR1 Stands to Profit From Healthy Deal Making
Biopharma companies backed by EcoR1 Capital have filed plans this week for public offerings.
These are busy times for the folks at Oleg Nodelman’s EcoR1 Capital, an investment firm focused on therapeutic companies in the biotechnology sector.Silverback Therapeutics, a clinical-stage biopharmaceutical company backed by EcoR1 Capital, filed plans with regulators this week to go public. On the same day, EcoR1-backed Oric Pharmaceuticals announced it was
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.